Work

Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.1098

Authors: Wassim McHayleh, Sara M. Tolaney, Virginia G. Kaklamani, Mridula Annette George, Aditya Bardia, Erika P. Hamilton, Nancy Chan, Vicente Valero, Anja Williams, Jo Chien, Yuan Yuan, Paula Muñoz Romero, Faten Koraichi Auriol, Jennifer A. Crozier, Tomer Wasserman, Hope S. Rugo

Institutions: AdventHealth Orlando, AdventHealth, Dana-Farber Cancer Institute, The University of Texas at San Antonio Health Science Center, Rutgers Cancer Institute, University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center, Sarah Cannon, NYU Langone Health, The University of Texas MD Anderson Cancer Center, Sarah Cannon Research Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Cedars-Sinai Medical Center, Menarini Group (Italy), City Of Hope National Medical Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Menarini Group

OpenAlex ID: W7162564997

Cites:

Cited by:

Related to: